Aggressive Metastatic Insulinoma in a Patient of Diabetes Mellitus with Documentation on Dual-Tracer PET-CT ([68Ga]Ga-DOTATATE and [18F]FDG): Clinical Benefits with Combined Chemo-PRRT Approach

Abstract

Insulinoma is a relatively uncommon pancreatic neuroendocrine tumor, with approximately 10% of the cases being malignant. Diabetes mellitus (DM) with concurrent insulinoma is very rare and the diagnosis of such condition is easily missed as it can be misconstrued as improved glycemic control. Therefore, persistent hypoglycemic symptoms even after stopping antidiabetic medications may be considered for insulinoma. Herein, we present a patient with DM and pancreatic insulinoma with extensive hepatic and skeletal metastases on dual-tracer positron emission tomography/computed tomography (PET/CT) ([68Ga]Ga-DOTATATE and [18F]fluorodeoxyglucose). Given the extensive disease, the patient was treated with a combination of peptide receptor radionuclide therapy (PRRT) and chemotherapy (capecitabine and temozolomide). During therapy, patient showed early clinical and imaging response for insulinoma leading to unmasking of poor glycemic control necessitating requirement of insulin administration for DM. The patient did not experience any life-threatening hypoglycemia during the chemo-PRRT treatment and showed an improvement in quality of life. Unfortunately, the disease progressed at the 4th cycle, 10 months after the initiation of PRRT. We conclude that combined chemo-PRRT may be considered an effective treatment option for patients with metastatic insulinoma and DM owing to its favorable imaging response and effective symptom control.

Keywords

insulinoma - pancreatic neuroendocrine tumor - diabetes mellitus - peptide receptor radionuclide therapy - chemo-PRRT - [68Ga]Ga-DOTATATE-PET/CT and [18F]FDG-PET/CT scans

Publikationsverlauf

Artikel online veröffentlicht:
24. Juli 2024

• References

• 1 Anderson CW, Bennett JJ. Clinical presentation and diagnosis of pancreatic neuroendocrine tumors. Surg Oncol Clin N Am 2016; 25 (02) 363-374
• 2 Parghane RV, Ostwal V, Ramaswamy A. et al. Long-term outcome of “Sandwich” chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease. Eur J Nucl Med Mol Imaging 2021; 48 (03) 913-923
• 3 Sitani K, Parghane RV, Talole S, Basu S. Long-term outcome of indigenous ¹⁷⁷Lu-DOTATATE PRRT in patients with metastatic advanced neuroendocrine tumours: a single institutional observation in a large tertiary care setting. Br J Radiol 2021; 94 (1117) 20201041
• 4 Sada A, Yamashita TS, Glasgow AE. et al. Comparison of benign and malignant insulinoma. Am J Surg 2021; 221 (02) 437-447
• 5 Peltola E, Hannula P, Huhtala H. et al. Long-term morbidity and mortality in patients diagnosed with an insulinoma. Eur J Endocrinol 2021; 185 (04) 577-586
• 6 Kane LA, Grant CS, Nippoldt TB, Service FJ. Insulinoma in a patient with NIDDM. Diabetes Care 1993; 16 (09) 1298-1300
• 7 Kunieda T, Yamakita N, Yasuda K. Insulinoma in a patient with type 2 diabetes mellitus proved at autopsy. Endocr Pract 2012; 18 (06) 1038
• 8 Pavel M, Öberg K, Falconi M. et al; ESMO Guidelines Committee. Electronic address: [e-mail]. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31 (07) 844-860
• 9 Brown E, Watkin D, Evans J, Yip V, Cuthbertson DJ. Multidisciplinary management of refractory insulinomas. Clin Endocrinol (Oxf) 2018; 88 (05) 615-624
• 10 Maggio I, Mollica V, Brighi N. et al. The functioning side of the pancreas: a review on insulinomas. J Endocrinol Invest 2020; 43 (02) 139-148
• 11 Rogers JE, Lam M, Halperin DM, Dagohoy CG, Yao JC, Dasari A. Fluorouracil, doxorubicin with streptozocin and subsequent therapies in pancreatic neuroendocrine tumors. Neuroendocrinology 2022; 112 (01) 34-42
• 12 Tovazzi V, Ferrari VD, Dalla Volta A, Consoli F, Amoroso V, Berruti A. Should everolimus be stopped after radiological progression in metastatic insulinoma? A “cons” point of view. Endocrine 2020; 69 (03) 481-484
• 13 Zandee WT, Brabander T, Blažević A. et al. Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 2019; 104 (04) 1336-1344
• 14 Friebe L, Freitag MT, Braun M. et al. Peptide receptor radionuclide therapy is effective for clinical control of symptomatic metastatic insulinoma: a long-term retrospective analysis. J Nucl Med 2024; 65 (02) 228-235
• 15 Kumar S, Melek M, Rohl P. Case report: hypoglycemia due to metastatic insulinoma in insulin-dependent type 2 diabetes successfully treated with 177 Lu-DOTATATE. Front Endocrinol (Lausanne) 2022; 13: 906012
• 16 Magalhães D, Sampaio IL, Ferreira G. et al. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review. J Endocrinol Invest 2019; 42 (03) 249-260